ANI Pharma acquires Atacand, Atacand HCT, Arimidex and Casodex US rights from AstraZeneca.

ANI Pharmaceuticals, Inc. announced that it has acquired the NDAs and U.S. rights to market Atacand, Atacand HCT, Arimidex, and Casodex from AstraZeneca for $46.5 million in cash, royalties, and sales-based milestones. AstraZeneca will continue to market and supply Atacand, Atacand HCT, Arimidex, and Casodex outside of the U.S. The acquired assets include the NDAs for all four products and a license to their trademarks. The acquisitions were funded through a combination of cash and debt. Collectively, these products generated approximately $19 million in U.S. market sales during the trailing twelve months through October 2017, according to IMS Health.